Home › Triple-Negative Breast Cancer › Texas
Triple-Negative Breast Cancer clinical trials in Texas
59 studies for Triple-Negative Breast Cancer are looking for participants at sites in Texas.
Cities in Texas
- Houston42 studies
- San Antonio23 studies
- Dallas18 studies
- Austin13 studies
- Fort Worth7 studies
- Irving4 studies
- Lewisville3 studies
- Abilene3 studies
- El Paso3 studies
177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
- MD Anderson Cancer Center, Houston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT07189871First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer
- MD Anderson Cancer Center, Houston
- NEXT Oncology, San Antonio
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT06799065Study of AVZO-021 in Patients With Advanced Solid Tumors
- Avenzo Therapeutics Recruiting Site, Dallas
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT05867251A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
- NEXT Oncology, Austin
- UT Southwestern, Dallas
RecruitingPhase 1
Ages 19 and older · All sexes · Updated Sep 28, 2026 · NCT06586957Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
- Hendrick Medical Center ( Site 0117), Abilene
- Harrington Cancer Center ( Site 0061), Amarillo
- Texas Oncology - DFW ( Site 8000), Dallas
- and 9 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06393374Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy
- M D Anderson Cancer Center, Houston
Recruiting
Ages 30 and older · Women · Updated Sep 25, 2026 · NCT02945579A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
- Texas Oncology - DFW ( Site 8007), Dallas
- Texas Oncology - West Texas ( Site 8004), El Paso
- Kelsey-Seybold Clinic - North Houston Campus ( Site 0096), Houston
- and 2 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06841354A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- Hendrick Medical Center ( Site 0009), Abilene
- Texas Oncology - DFW ( Site 8009), Dallas
- UT Southwestern ( Site 0092), Dallas
- and 7 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06966700A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
- NEXT Oncology - Irving, Irving
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT06618287Intratumoral N17350 in Advanced Solid Tumors
- The University of Texas MD Anderson Cancer Center, Houston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT07339176Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
- Oncology Consultants, P.A., Houston
- University of Texas M.D. Anderson Cancer Center, Houston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 21, 2026 · NCT05983432A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors
- The University of Texas MD Anderson Cancer Center, Houston
- NEXT Oncology, San Antonio
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 18, 2026 · NCT07705334Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies
- Baylor College of Medicine, Houston
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 18, 2026 · NCT07340541A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
- MD Anderson Cancer Center, Houston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 17, 2026 · NCT07020117The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- New Experimental Therapeutics - NEXT Oncology, Austin
- Texas Oncology, Bedford
- UT Southwest Simmons Cancer Center, Dallas
- and 2 more
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Sep 15, 2026 · NCT04585750First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
- NEXT Oncology Austin, Austin
- NEXT Oncology - Dallas, Irving
- NEXT Oncology - San Antonio, San Antonio
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 11, 2026 · NCT06657222Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
- Texas Oncology, Austin
- Texas Oncology, El Paso
- MD Anderson Cancer Center, Houston
- and 1 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 9, 2026 · NCT05633654A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
- The University of Texas - MD Anderson Cancer Center, Houston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 4, 2026 · NCT06400472A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- University of Texas MD Anderson Cancer Center, Houston
- South Texas Accelerated Research Therapeutics (START), San Antonio
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 4, 2026 · NCT06465069Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
- UT Health Houston, Houston
RecruitingObservational study
Ages 18 to 99 · All sexes · Updated Sep 3, 2026 · NCT07211178A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
- University of Texas Southwestern Medical Center, Dallas
- MD Anderson Cancer Center, Houston
- South Texas Accelerated Research Therapeutics (START) San Antonio, San Antonio
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 28, 2026 · NCT07029399Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
- START-San Antonio, San Antonio
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 24, 2026 · NCT06084481A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
- Research Site, Houston
- Research Site, San Antonio
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 19, 2026 · NCT07115043A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
- Normunity Investigational Site, Dallas
- Normunity Investigational Site, Houston
- Normunity Investigational Site, San Antonio
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 18, 2026 · NCT07182149A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
- Houston Methodist Hospital, Houston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 17, 2026 · NCT04895709Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
- START San Antonio, San Antonio
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 13, 2026 · NCT05985655SMP-3124LP in Adults With Advanced Solid Tumors
- MD Anderson Cancer Center, Houston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 12, 2026 · NCT06526819A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
- Texas Oncology - Central/South Texas, Austin
- Texas Oncology - West Texas, El Paso
- Texas Oncology - Northeast Texas, Flower Mound
- and 1 more
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Aug 10, 2026 · NCT06926868Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer
- UT MD Anderson Cancer Center, Houston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 10, 2026 · NCT05111561A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors
- Clinical Trial Site, San Antonio
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 6, 2026 · NCT07749586Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- USOR Texas Oncology, Abilene
- Texas Oncology - Central / South Texas, Austin
- Mary Crowley Cancer Research, Dallas
- and 3 more
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 4, 2026 · NCT05579366A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
- NEXT Austin, Austin
- START Center for Clinical Research, Fort Worth
- University of Texas MD Anderson Cancer Center, Houston
- and 1 more
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 3, 2026 · NCT06270706Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
- Uni Of TX MD Anderson Cancer Cntr, Houston
RecruitingPhase 1
Ages 18 to 100 · All sexes · Updated Jul 29, 2026 · NCT06562192A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors
- The University of Texas MD Anderson Cancer Center - Conroe, Conroe
- The University of Texas - M.D. Anderson Cancer Center, Houston
- The University of Texas, MD Anderson Cancer Center - West Houston, Houston
- and 3 more
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 22, 2026 · NCT07318805A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
- University of Texas Southwestern Medical Center - Simmons Cancer Center, Dallas
- UT Southwestern Medical Center - Redbird, Dallas
- Univ. of TX Southwestern Medical Center - Zale Lipshy University Hospital, Dallas
- and 8 more
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 22, 2026 · NCT05208762Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC)
- The University of Texas M. D. Anderson Cancer Center, Houston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jul 7, 2026 · NCT07011654Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)
- JPS Health Network, Forth Worth
- Baylor Scott and White Biorepository, Temple
RecruitingObservational study
Ages 18 and older · All sexes · Updated Jun 29, 2026 · NCT07327489A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
- Texas Oncology, P.A., Dallas
- MD Anderson, Houston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jun 29, 2026 · NCT05377996A Study of LY4175408 in Participants With Advanced Cancer
- MD Anderson Cancer Center, Houston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jun 23, 2026 · NCT07046923Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
- NEXT Oncology Austin /ID# 243005, Austin
- The University of Texas MD Anderson Cancer Center /ID# 270059, Houston
- Next Oncology Dallas /ID# 276254, Irving
- and 2 more
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jun 23, 2026 · NCT05005403From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.